List of Boniva drug patents

Boniva is owned by Hoffmann La Roche.

Boniva contains Ibandronate Sodium.

Boniva has a total of 3 drug patents out of which 0 drug patents have expired.

Boniva was authorised for market use on 16 May, 2003.

Boniva is available in tablet;oral dosage forms.

Boniva can be used as treatment and prevention of osteoporosis, treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid.

The generics of Boniva are possible to be released after 06 May, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid
May, 2023

(2 months from now)

US7718634 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid
May, 2023

(2 months from now)

US7410957 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid
May, 2023

(2 months from now)

Drugs and Companies using IBANDRONATE SODIUM ingredient

Market Authorisation Date: 16 May, 2003

Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention of osteoporosis

Dosage: TABLET;ORAL

How can I launch a generic of BONIVA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic